KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Deferred Taxes (2016 - 2025)

Biogen (BIIB) has 17 years of Deferred Taxes data on record, last reported at $166.9 million in Q4 2025.

  • For Q4 2025, Deferred Taxes rose 385.79% year-over-year to $166.9 million; the TTM value through Dec 2025 reached $361.6 million, up 328.72%, while the annual FY2025 figure was $361.6 million, 328.72% up from the prior year.
  • Deferred Taxes reached $166.9 million in Q4 2025 per BIIB's latest filing, down from $253.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $323.3 million in Q4 2021 and bottomed at -$607.8 million in Q2 2021.
  • Average Deferred Taxes over 5 years is -$34.9 million, with a median of -$39.9 million recorded in 2022.
  • Peak YoY movement for Deferred Taxes: surged 613.99% in 2021, then tumbled 6550.0% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at $323.3 million in 2021, then tumbled by 108.91% to -$28.8 million in 2022, then surged by 349.65% to $71.9 million in 2023, then crashed by 181.22% to -$58.4 million in 2024, then skyrocketed by 385.79% to $166.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $166.9 million in Q4 2025, $253.8 million in Q3 2025, and -$31.3 million in Q2 2025.